The DOI matches its Crossref record; 13 of the 13 references it cites were found in a registry or an index.
Randomized Phase III Study of Gemcitabine-Cisplatin Versus Etoposide-Cisplatin in the Treatment of Locally Advanced or Metastatic Non–Small-Cell Lung Cancer
Abstract
PURPOSE: We conducted a randomized trial to compare gemcitabine-cisplatin with etoposide-cisplatin in the treatment of patients with advanced non–small-cell lung cancer (NSCLC). The primary end point of the comparison was response rate. PATIENTS AND METHODS: A total of 135 chemotherapy-naive patients with advanced NSCLC were randomized to receive either gemcitabine 1,250 mg/m 2 intravenously (IV) days 1 and 8 or etoposide 100 mg/m 2 IV days 1 to 3 along with cisplatin 100 mg/m 2 IV day 1. Both treatments were administered in 21-day cycles. One hundred thirty-three patients were included in the intent-to-treat analysis of response. RESULTS: The response rate (externally validated) for patients given gemcitabine-cisplatin was superior to that for patients given etoposide-cisplatin (40.6% v 21.9%; P = .02). This superior response rate was associated with a significant delay in time to disease progression (6.9 months v 4.3 months; P = .01) without an impairment in quality of life (QOL). There was no statistically significant difference in survival time between both arms (8.7 months for gemcitabine-cisplatin v 7.2 months for etoposide-cisplatin; P = .18). The overall toxicity profile for both combinations of drugs was similar. Nausea and vomiting were reported more frequently in the gemcitabine arm than in the etoposide arm. However, the difference was not significant. Gemcitabine-cisplatin produced less grade 3 alopecia (13% v 51%) and less grade 4 neutropenia (28% v 56% ) but more grade 3 and 4 thrombocytopenia (56% v 13%) than did etoposide-cisplatin. However, there were no thrombocytopenia-related complications in the gemcitabine arm. CONCLUSION: Compared with etoposide-cisplatin, gemcitabine-cisplatin provides a significantly higher response rate and a delay in disease progression without impairing QOL in patients with advanced NSCLC.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Aaronson, N. K., Ahmedzai, S., Bergman, B., Bullinger, M., Cull, A., Duez, N. J., Filiberti, A., Flechtner, H., Fleishman, S. B., Haes, J. C. J. M. D., et al. (1993) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/85.5.365 · Cited by 16,005
Non-small Cell Lung Cancer Collaborative Group (1995) · BMJ · doi:10.1136/bmj.311.7010.899 · Cited by 2,850
Bergman, B., Aaronson, N. K., Ahmedzai, S., Kaasa, S., & Sullivan, M. (1994) · European Journal of Cancer · doi:10.1016/0959-8049(94)90535-5 · Cited by 885
Polychemotherapy in advanced non small cell lung cancer: a meta-analysis
Bernard, J. P., Souquet, P. J., Boissel, J. P., Chauvin, F., Cellerino, R., Tumarello, D., Cormier, Y., Ganz, P. A., Kaasa, S., Pater, J. L., et al. (1993) · The Lancet · doi:10.1016/0140-6736(93)91882-m · Cited by 490
Chemotherapy for advanced non-small-cell lung cancer: how much benefit is enough?
Grilli, R., Oxman, A. D., & Julian, J. A. (1993) · Journal of Clinical Oncology · doi:10.1200/jco.1993.11.10.1866 · Cited by 382
Anderson, H., Lund, B., Bach, F., Thatcher, N., Walling, J., & Hansen, H. H. (1994) · Journal of Clinical Oncology · doi:10.1200/jco.1994.12.9.1821 · Cited by 374
Efficacy and safety profile of gemcitabine in non-small-cell lung cancer: a phase II study.
Abratt, R. P., Bezwoda, W. R., Falkson, G., Goedhals, L., Hacking, D., & Rugg, T. A. (1994) · Journal of Clinical Oncology · doi:10.1200/jco.1994.12.8.1535 · Cited by 359
Cisplatin-gemcitabine combination in advanced non-small-cell lung cancer: a phase II study.
Crinò, L., Scagliotti, G., Marangolo, M., Figoli, F., Clerici, M., De Marinis, F., Salvati, F., Cruciani, G., Dogliotti, L., Pucci, F., et al. (1997) · Journal of Clinical Oncology · doi:10.1200/jco.1997.15.1.297 · Cited by 303
Chemotherapy vs Supportive Care in Advanced Non-Small-Cell Lung Cancer
Marino, P., Pampallona, S., Preatoni, A., Cantoni, A., & Invernizzi, F. (1994) · Chest · doi:10.1378/chest.106.3.861 · Cited by 299
Abratt, R. P., Bezwoda, W. R., Goedhals, L., & Hacking, D. J. (1997) · Journal of Clinical Oncology · doi:10.1200/jco.1997.15.2.744 · Cited by 177
Perng, R. P., Chen, Y. M., Liu, J. M., Tsai, C.-M., Lin, W., Yang, K., & Whang‐Peng, J. (1997) · Journal of Clinical Oncology · doi:10.1200/jco.1997.15.5.2097 · Cited by 148
ON THE RELATIONSHIP BETWEEN RESPONSE TO TREATMENT AND SURVIVAL TIME
Buyse, M. E., & Piedbois, P. (1996) · Statistics in Medicine · doi:10.1002/(sici)1097-0258(19961230)15:24<2797::aid-sim290>3.0.co;2-v · Cited by 133
Preclinical combination therapy with gemcitabine and mechanisms of resistance.
Peters, G. J., van Haperen, V. W. T. R., Bergman, A. M., Veerman, G., Smitskamp-Wilms, E., van Moorsel, C. J. A., Kuiper, C. M., & Braakhuis, B. J. M. (1996) · PubMed · Cited by 82
Cited by
Giaccone, G., Herbst, R. S., Manegold, C., Scagliotti, G., Rosell, R., Miller, V., Natale, R. B., Schiller, J. H., von Pawel, J., Pluzanska, A., et al. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2004.08.001 · Cited by 1,716
Self-citationPfister, D. G., Johnson, D. H., Azzoli, C. G., Sause, W., Smith, T. J., Baker Jr, S., Olak, J., Stover, D., Strawn, J. R., Turrisi, A. T., et al. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2004.09.053 · Cited by 1,413
Kelly, K., Crowley, J., Bunn, P. A., Presant, C. A., Grevstad, P. K., Moinpour, C. M., Ramsey, S. D., Wozniak, A. J., Weiss, G. R., Moore, D. F., et al. (2001) · Journal of Clinical Oncology · doi:10.1200/jco.2001.19.13.3210 · Cited by 1,123
Aapro, M. S., Bohlius, J., Cameron, D. A., Lago, L. D., Donnelly, J. P., Kearney, N., Lyman, G. H., Pettengell, R., Tjan-Heijnen, V. C., Walewski, J., et al. (2011) · European Journal of Cancer · doi:10.1016/j.ejca.2010.10.013 · Cited by 1,090
Scagliotti, G. V., De Marinis, F., Rinaldi, M., Crinò, L., Gridelli, C., Ricci, S., Matano, E., Boni, C., Marangolo, M., Failla, G., et al. (2002) · Journal of Clinical Oncology · doi:10.1200/jco.2002.02.068 · Cited by 889
Metadata
- Authors
- Cardenal, F., López-Cabrerizo, M. P., Antón, A., Alberola, V., Massuti, B., Carrato, A., Barneto, I., Lomas, M., García, M., Lianes, P., Montalar, J., Vadell, C., González-Larriba, J. L., Nguyen, B., Artal, A., & Rosell, R.
- Venue
- Journal of Clinical Oncology
- Published
- 1999-01
- Volume
- 17
- Issue
- 1
- Pages
- 12-12
- ISSN
- 0732-183X (ISSN-L)
- 1527-7755
- OpenAlex
- W2146014573
- Cited by
- 471
- References
- 13
- FWCI
- 42.41
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.